title: [Treatment of chronic ventricular extrasystole with propafenone (Rhythmonorm)].
abstract: Peroral treatment with rhythmonorm (Knoll AG--GFR) with 450 to 900 mg daily was carried out to 38 patients with an average age 52,2 +/- 2,34, with chronic ventricular extrasystole. In 89,50 per cent of the cases, complete inhibition of the ventricular extrasystoles was attained or reduction in their number with greater than 80 per cent, and that result, in 55,26 per cent, was attained within the first days of the treatment. The pulse rate was reduced with 10 per cent on the average by the end of the treatment. Significant changes in cardiac conductivity, arterial pressure and severe adverse effects were not observed. The preparation rhythmonorm is an effective, convenient to take and well tolerated agent for the treatment and prophylaxis of ventricular extrasystoles.
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D005117:Cardiac Complexes, Premature / Q000188:drug therapy* / Q000503:physiopathology; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D004562:Electrocardiography; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011405:Propafenone; D011427:Propiophenones / Q000627:therapeutic use*; D013607:Tablets
chemical_list: D000889:Anti-Arrhythmia Agents; D011427:Propiophenones; D013607:Tablets; D011405:Propafenone
vernacular_title: Lechenie na khronichna kamerna ekstrasistoliia s propafenon (ritmonorm).